BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of genomic sequencing services and proteomic services to academic institutions, pharmaceutical companies, health care providers and other organizations in China and internationally. The company offers DNA sequencing services covering whole genome sequencing, plant/animal whole genome sequencing, exome sequencing, de novo sequencing, and metagenomic … Read more
BGI Genomics Co Ltd (300676) - Total Assets
Latest total assets as of September 2025: CN¥12.30 Billion CNY
Based on the latest financial reports, BGI Genomics Co Ltd (300676) holds total assets worth CN¥12.30 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BGI Genomics Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how BGI Genomics Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BGI Genomics Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
BGI Genomics Co Ltd's total assets of CN¥12.30 Billion consist of 54.8% current assets and 45.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 31.4% |
| Accounts Receivable | CN¥1.75 Billion | 14.0% |
| Inventory | CN¥601.62 Million | 4.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥508.31 Million | 4.1% |
| Goodwill | CN¥36.47 Million | 0.3% |
Asset Composition Trend (2012–2024)
This chart illustrates how BGI Genomics Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BGI Genomics Co Ltd's current assets represent 54.8% of total assets in 2024, a decrease from 81.0% in 2012.
- Cash Position: Cash and equivalents constituted 31.4% of total assets in 2024, down from 35.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 14.0% of total assets.
BGI Genomics Co Ltd Competitors by Total Assets
Key competitors of BGI Genomics Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
BGI Genomics Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BGI Genomics Co Ltd generates 0.31x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BGI Genomics Co Ltd is currently not profitable relative to its asset base.
BGI Genomics Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.81 | 2.63 | 2.21 |
| Quick Ratio | 2.58 | 2.38 | 1.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.20 Billion | CN¥ 4.70 Billion | CN¥ 4.61 Billion |
BGI Genomics Co Ltd - Advanced Valuation Insights
This section examines the relationship between BGI Genomics Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.02 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -7.9% |
| Total Assets | CN¥12.54 Billion |
| Market Capitalization | $1.45 Billion USD |
Valuation Analysis
Below Book Valuation: The market values BGI Genomics Co Ltd's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: BGI Genomics Co Ltd's assets decreased by 7.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BGI Genomics Co Ltd (2012–2024)
The table below shows the annual total assets of BGI Genomics Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥12.54 Billion | -7.87% |
| 2023-12-31 | CN¥13.61 Billion | -5.30% |
| 2022-12-31 | CN¥14.38 Billion | +0.85% |
| 2021-12-31 | CN¥14.25 Billion | +27.32% |
| 2020-12-31 | CN¥11.20 Billion | +89.45% |
| 2019-12-31 | CN¥5.91 Billion | +12.52% |
| 2018-12-31 | CN¥5.25 Billion | +2.73% |
| 2017-12-31 | CN¥5.11 Billion | +20.84% |
| 2016-12-31 | CN¥4.23 Billion | +8.16% |
| 2015-12-31 | CN¥3.91 Billion | +90.88% |
| 2014-12-31 | CN¥2.05 Billion | +36.83% |
| 2013-12-31 | CN¥1.50 Billion | +49.19% |
| 2012-12-31 | CN¥1.00 Billion | -- |